Share Holder’s Info

Reconciliation of Share Capital Audit Report_31-03-2025

Shareholding Pattern_31-03-2025

Reconciliation Of Share Capital Audit Report_31-12-2024

Shareholding Pattern_31-12-2024

Update on Acquisition of NJ Bio

Acquisition NJ Bio - Press Release & Investor Presentation

Acquisition NJ Bio - Stock Exchange Intimation

Shareholding Pattern_30-09-2024

Reconciliation Of Share Capital Audit Report_30-09-2024

Shareholding Pattern_30-06-2024

Reconciliation Of Share Capital Audit Report_30-06-2024

Annual Secretarial Compliance Report 2024

Compliance Certificate Reg40(10)_31-03-2024

Shareholding Pattern_31-03-2024

Reconciliation Of Share Capital Audit Report_31-03-2024

Shareholding Pattern_31-12-2023

Reconciliation Of Share Capital Audit Report_31-12-2023

Shareholding Pattern_30-09-2023

Reconciliation of Share Capital Audit Report_30-09-2023

Reconciliation of Share Capital Audit Report_30-06-2023

Shareholding Pattern_30-06-2023

Annual Secretarial Compliance Report 2023

Shareholding Pattern_31-03-2023

Reconciliation of Share Capital Audit Report_31-03-2023

Shareholding Pattern_31-12-2022

Reconciliation of Share Capital Audit Report_31-12-2022

Shareholding Pattern_30-09-2022

Reconciliation of Share Capital Audit Report_30-09-2022

Shareholding Pattern_30-06-2022

Reconciliation of Share Capital Audit Report_30-06-2022

Annual Secretarial Compliance Report 2022

Reconciliation of Share Capital Audit Report_31-03-2022

Shareholding Pattern_31-03-2022

ComplianceCertificateReg40(10)_31-03-2022

Reconciliation of Share Capital Audit Report_31-12-2021

Shareholding Pattern_31-12-2021

Reconciliation of Share Capital Audit Report_30-09-2021

Shareholding Pattern_30-09-2021

Reconciliation of Share Capital Audit Report_30-06-2021

Shareholding Pattern_30-06-2021

Annual Secretarial Compliance Report 2021

Reconciliation of Share Capital Audit Report_31-03-2021

Compliance Certificate_Reg40(10)_ 31-03-2021

Shareholding Pattern_31-03-2021

Shareholding Pattern_31-12-2020

Reconciliation of Share Capital Audit Report_31-12-2020

Compliance Certificate_Reg40(10)_ 30-09-2020

Reconciliation of Share Capital Audit Report_30-09-2020

Shareholding Pattern_30-09-2020

Reconciliation of Share Capital Audit Report_30-06-2020

Shareholding Pattern_30-06-2020

Shareholding Pattern_31-03-2020

Reconciliation of Share Capital Audit Report_31-03-2020

Compliance Certificate_Reg40(10)_31-03-2020

Scrutinizer's Report of the AGM 2024

Scrutinizer's Report of the AGM 2023

Scrutinizer's Report of the AGM 2022

Scrutinizer's Report of the AGM 2021

Scrutinizer's Report of the AGM 2020

FY 2025-2026

Notice of Board Meeting to be held on Wednesday, the May 28, 2025

FY 2024-2025

Notice of Board Meeting to be held on Wednesday, the 12th February, 2025

Notice Of Board Meeting To Be Held On Tuesday, The 12th November, 2024

Notice Of Board Meeting To Be Held On Friday, The 9th August, 2024

Notice Of Board Meeting To Be Held On Thursday, The 30th May, 2024

FY 2023-2024

Notice Of Board Meeting To Be Held On Monday, The 5th February, 2024

Notice Of Board Meeting To Be Held On Thursday, The 9th November, 2023

Notice Of Board Meeting To Be Held On Thursday, The 9th November, 2023

Notice of Board Meeting to be held on Tuesday, the 8th August, 2023

Notice of Board Meeting to be held on Thursday, the 25th May, 2023

FY 2022-2023

Notice of Board Meeting to be held on Monday, the 06th February, 2023

Notice of Board Meeting to be held on Tuesday, the 08th November, 2022

Notice of Board Meeting to be held on Monday, the 08th August, 2022

Notice of Board Meeting to be held on Monday, the 09th May, 2022

FY 2021-2022

Notice of Board Meeting to be held on Tuesday, the 08th February, 2022

Notice of Board Meeting to be held on Friday, the 13th August, 2021

Notice of Board Meeting to be held on Tuesday, the 8th June, 2021

Notice of Board Meeting to be held on Saturday, the 06th November, 2021

FY 2023-2024

Intimation of change in control of the Company and change in directors of the Company

FY 2020-2021

February 10, 2021: Communication regarding deduction of tax at source on Dividend

Information Memorandum 04-March-2020

Apportionment of Cost of Acquisition of Shares - SLSL & SPL

Suven Pharmaceuticals Demerger Listing PA Clipping Financial Express 05.03.2020

Suven Pharmaceuticals Demerger Listing PA Clipping Nava Telangana 05.03.2020

Suven Pharmaceuticals Demerger Listing PA Clipping Jansatta 05.03.2020

Unclaimed Dividend as on March 31, 2024

Unclaimed Dividend as on March 31, 2023

Unpaid Dividend

Stock Exchange Intimation IDC Recommendations October 17, 2023

Scrutinizer Report of PB for Appointment of Directors

Notice of Postal Ballot Nov-2024

Scrutinizer Report of PB for ESOP

Notice of Postal Ballot Dec-2023-24

Scrutinizer Report of PB for Shifting of Regd. Office

Notice of Postal Ballot 2023-24

Scheme of Amalgamation - Casper (WOS) into and with Suven Pharma

Update on Merger - Casper (WOS) into and with Suven Pharma

NCLT Order Sanctioning Scheme - Casper (WOS) into and with Suven Pharma

Notice of Hearing of Company Petition

Advertisement regarding Notice of Hearing of Company Petition

Draft Scheme - Casper (WOS) into and with Suven Pharma

Scheme of Amalgamation - Cohance into and with Suven Pharma

Allotment of shares pursuant to Scheme of Amalgamation

Intimation of Effective Date of Merger and Record Date

Intimation of DOP Approval – Merger of Cohance into and with Suven Pharma

Order copy issued by Hon`ble NCLT – Merger of Cohance with and into Suven Pharma

Summary of Proceedings, Voting Results and Scrutinizer’s Report of the NCLT convened Shareholders Meeting

Newspaper Publication - Notice of General Meeting

Notice of NCLT Convened Shareholders Meeting

Summary working of proposed amalgamation

Additional documents submitted to Stock Exchanges

Copy of NCLT Order dated 22.10.2024

Observation Letter - BSE

Observation Letter - NSE

Complaints Report - NSE

Complaints Report - BSE

Draft Scheme

Valuation Report

Fairness Opinion

Audit Committee Report

Independent Directors Committee Report

Pre-Post Shareholding Pattern

Accounting Treatment Certificate

Audited Financials on unlisted company

Declaration for No Past Defaults

Compliance Report

2025-26

Q4_Schedule of Conference Call for Investors on May 28, 2025

Change in name and trading symbol

Allotment of shares pursuant to Scheme of Amalgamation

Press Release regarding change in name of the Company

Change in Name of the Company

Press Release – Effective date for Scheme of Amalgamation

Intimation of Effective Date of Merger and Record Date

Cautionary Email from NSE

Cautionary Email from BSE

2024-25

Schedule of B&K, Macquarie Roadshow on March 31, April 1, 2 & 3, 2025

USFDA Audit Related Press Release – Cohance

Schedule of Conferences on March 11 & 12, 2025

Schedule of B&K Roadshow on February 28, 2025

Analyst Day on February 27, 2025

Schedule of Conferences on February14 – 21, 2025

Investor Presentation – January 2025

Schedule of Conferences/Roadshows on January 13 – 16, 2025

Update on Acquisition of NJ Bio

Acquisition NJ Bio – Schedule of Conference Call for Investors_09122024

Acquisition NJ Bio – Press Release & Investor Presentation

Acquisition NJ Bio – Stock Exchange Intimation

Schedule of Conferences/Roadshows on December 5, 2024

Schedule of meet on December 4, 2024

Credit Rating 29-Nov-2024

Schedule of Conference/Roadshow on November 25, 2024

Schedule of conferences/roadshows

Schedule of Conference Call for Investors on June 19, 2024

Outcome of Board Meeting 13/06/2024

Outcome of Board Meeting 30/05/2024

Schedule of Conference Call for Investors on May 30, 2024

2023-24

Schedule of Conference Call for Investors on November 12, 2024

Schedule of Analyst Meet on September 30, 2024

Outcome of Board Meeting 19/09/2024

Schedule of Analyst Meet on September 18, 2024

Credit Rating 05-Sept-2024

Schedule of Analyst Meet on September 11, 2024

Schedule of Analyst Meet on September 04, 2024

Schedule of Analyst Meet on August 22, 2024

Schedule of Conference Call for Investors on August 09, 2024

Schedule of Analyst Meet on March 27, 2024

Credit Rating 11-Mar-2024

Press Release 29th Feb’24

Schedule of Conference Call for Investors on March 05, 2024

Investor Presentation 29th Feb’24

Outcome of Board Meeting 29/02/2024

Outcome of Board Meeting 29/02/2024

Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015

Outcome of Board Meeting 05/02/2024

Disclosure under Regulation 31A(8)(d)

Disclosure under Regulation 31A

Outcome of Board Meeting 29/09/2023

Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 29 09/2023

Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 26/09/2023

Schedule of Conference Call for Investors on August 10, 2023

Schedule of Conference Call for Investors on May 26, 2023

Disclosure under Regulation 30 of LODR

Schedule of Conference Call for Investors on February 7, 2023

2022-23

Conference Call Transcript on December 26, 2022

Conference Call Audio on December 26, 2022

Schedule of Conference Call for Investors on December 26, 2022

Disclosure under Regulation 30

Schedule of Conference Call for Investors on November 9, 2022

Casper Pharma Receives EIR from USFDA for its PAI (pre-approval inspection)

Outcome of the Board Meeting 02/09/2022

Schedule of Conference Call for Investors on August 08, 2022

Casper Pharma completed USFDA pre-approval inspection

Transcript of the earnings for the Analyst Meet on June 01, 2022

Analyst Meet Audio recording on June 01, 2022

Schedule of Analyst Meet on June 01, 2022

Schedule of Conference Call for Investors on May 10, 2022

SUVENPHARM Outcome of Board Meeting 05-04-2022

2021-22

SUVENPHARM Outcome of Board Meeting 14-12-2021

SUVENPHARM News Release 10062021

2021-22

SUVENPHARM Outcome of Board Meeting 14-12-2021

SUVENPHARCovidNewsRelease25032020

Reconciliation of Share Capital Audit Report_31-03-2025

Shareholding Pattern_31-03-2025

Reconciliation Of Share Capital Audit Report_31-12-2024

Shareholding Pattern_31-12-2024

Update on Acquisition of NJ Bio

Acquisition NJ Bio - Press Release & Investor Presentation

Acquisition NJ Bio - Stock Exchange Intimation

Shareholding Pattern_30-09-2024

Reconciliation Of Share Capital Audit Report_30-09-2024

Shareholding Pattern_30-06-2024

Reconciliation Of Share Capital Audit Report_30-06-2024

Annual Secretarial Compliance Report 2024

Compliance Certificate Reg40(10)_31-03-2024

Shareholding Pattern_31-03-2024

Reconciliation Of Share Capital Audit Report_31-03-2024

Shareholding Pattern_31-12-2023

Reconciliation Of Share Capital Audit Report_31-12-2023

Shareholding Pattern_30-09-2023

Reconciliation of Share Capital Audit Report_30-09-2023

Reconciliation of Share Capital Audit Report_30-06-2023

Shareholding Pattern_30-06-2023

Annual Secretarial Compliance Report 2023

Shareholding Pattern_31-03-2023

Reconciliation of Share Capital Audit Report_31-03-2023

Shareholding Pattern_31-12-2022

Reconciliation of Share Capital Audit Report_31-12-2022

Shareholding Pattern_30-09-2022

Reconciliation of Share Capital Audit Report_30-09-2022

Shareholding Pattern_30-06-2022

Reconciliation of Share Capital Audit Report_30-06-2022

Annual Secretarial Compliance Report 2022

Reconciliation of Share Capital Audit Report_31-03-2022

Shareholding Pattern_31-03-2022

ComplianceCertificateReg40(10)_31-03-2022

Reconciliation of Share Capital Audit Report_31-12-2021

Shareholding Pattern_31-12-2021

Reconciliation of Share Capital Audit Report_30-09-2021

Shareholding Pattern_30-09-2021

Reconciliation of Share Capital Audit Report_30-06-2021

Shareholding Pattern_30-06-2021

Annual Secretarial Compliance Report 2021

Reconciliation of Share Capital Audit Report_31-03-2021

Compliance Certificate_Reg40(10)_ 31-03-2021

Shareholding Pattern_31-03-2021

Shareholding Pattern_31-12-2020

Reconciliation of Share Capital Audit Report_31-12-2020

Compliance Certificate_Reg40(10)_ 30-09-2020

Reconciliation of Share Capital Audit Report_30-09-2020

Shareholding Pattern_30-09-2020

Reconciliation of Share Capital Audit Report_30-06-2020

Shareholding Pattern_30-06-2020

Shareholding Pattern_31-03-2020

Reconciliation of Share Capital Audit Report_31-03-2020

Compliance Certificate_Reg40(10)_31-03-2020

Scrutinizer's Report of the AGM 2024

Scrutinizer's Report of the AGM 2023

Scrutinizer's Report of the AGM 2022

Scrutinizer's Report of the AGM 2021

Scrutinizer's Report of the AGM 2020

FY 2025-2026

Notice of Board Meeting to be held on Wednesday, the May 28, 2025

FY 2024-2025

Notice of Board Meeting to be held on Wednesday, the 12th February, 2025

Notice Of Board Meeting To Be Held On Tuesday, The 12th November, 2024

Notice Of Board Meeting To Be Held On Friday, The 9th August, 2024

Notice Of Board Meeting To Be Held On Thursday, The 30th May, 2024

FY 2023-2024

Notice Of Board Meeting To Be Held On Monday, The 5th February, 2024

Notice Of Board Meeting To Be Held On Thursday, The 9th November, 2023

Notice Of Board Meeting To Be Held On Thursday, The 9th November, 2023

Notice of Board Meeting to be held on Tuesday, the 8th August, 2023

Notice of Board Meeting to be held on Thursday, the 25th May, 2023

FY 2022-2023

Notice of Board Meeting to be held on Monday, the 06th February, 2023

Notice of Board Meeting to be held on Tuesday, the 08th November, 2022

Notice of Board Meeting to be held on Monday, the 08th August, 2022

Notice of Board Meeting to be held on Monday, the 09th May, 2022

FY 2021-2022

Notice of Board Meeting to be held on Tuesday, the 08th February, 2022

Notice of Board Meeting to be held on Friday, the 13th August, 2021

Notice of Board Meeting to be held on Tuesday, the 8th June, 2021

Notice of Board Meeting to be held on Saturday, the 06th November, 2021

FY 2023-2024

Intimation of change in control of the Company and change in directors of the Company

FY 2020-2021

February 10, 2021: Communication regarding deduction of tax at source on Dividend

Information Memorandum 04-March-2020

Apportionment of Cost of Acquisition of Shares - SLSL & SPL

Suven Pharmaceuticals Demerger Listing PA Clipping Financial Express 05.03.2020

Suven Pharmaceuticals Demerger Listing PA Clipping Nava Telangana 05.03.2020

Suven Pharmaceuticals Demerger Listing PA Clipping Jansatta 05.03.2020

Unclaimed Dividend as on March 31, 2024

Unclaimed Dividend as on March 31, 2023

Unpaid Dividend

Stock Exchange Intimation IDC Recommendations October 17, 2023

Scrutinizer Report of PB for Appointment of Directors

Notice of Postal Ballot Nov-2024

Scrutinizer Report of PB for ESOP

Notice of Postal Ballot Dec-2023-24

Scrutinizer Report of PB for Shifting of Regd. Office

Notice of Postal Ballot 2023-24

Scheme of Amalgamation - Casper (WOS) into and with Suven Pharma

Update on Merger - Casper (WOS) into and with Suven Pharma

NCLT Order Sanctioning Scheme - Casper (WOS) into and with Suven Pharma

Notice of Hearing of Company Petition

Advertisement regarding Notice of Hearing of Company Petition

Draft Scheme - Casper (WOS) into and with Suven Pharma

Scheme of Amalgamation - Cohance into and with Suven Pharma

Allotment of shares pursuant to Scheme of Amalgamation

Intimation of Effective Date of Merger and Record Date

Intimation of DOP Approval – Merger of Cohance into and with Suven Pharma

Order copy issued by Hon`ble NCLT – Merger of Cohance with and into Suven Pharma

Summary of Proceedings, Voting Results and Scrutinizer’s Report of the NCLT convened Shareholders Meeting

Newspaper Publication - Notice of General Meeting

Notice of NCLT Convened Shareholders Meeting

Summary working of proposed amalgamation

Additional documents submitted to Stock Exchanges

Copy of NCLT Order dated 22.10.2024

Observation Letter - BSE

Observation Letter - NSE

Complaints Report - NSE

Complaints Report - BSE

Draft Scheme

Valuation Report

Fairness Opinion

Audit Committee Report

Independent Directors Committee Report

Pre-Post Shareholding Pattern

Accounting Treatment Certificate

Audited Financials on unlisted company

Declaration for No Past Defaults

Compliance Report

Stock Information

World class manufacturing facilities in the business of Pharmaceuticals and Fine Chemical Intermediates for Global Pharma Companies for New Chemical Entities (NCE’s) as the thrust area.

Quick Links

About Us

Research & Facilities

Business Segments

Investors

Sustainability & Social Responsibility

Corporate Office :

Suven Pharmaceuticals Ltd.

202, A-Wing, Galaxy Towers, Plot No-1, Hyderabad Knowledge City, TSIIC, Raidurg, Serilingampally, Rangareddy District, Hyderabad-500081 Telangana, India

+91-40-2354-9414 /3311

info@suvenpharm.com

Registered Office:

Suven Pharmaceuticals Ltd.

215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India

CIN : L24299MH2018PLC422236

Reach Us | Terms Of Use | Privacy Policy

World class manufacturing facilities in the business of Pharmaceuticals and Fine Chemical Intermediates for Global Pharma Companies for New Chemical Entities (NCE’s) as the thrust area.

Quick Links

About Us

Research & Facilities

Business Segments

Investors

Sustainability & Social Responsibility

Corporate Office :

Suven Pharmaceuticals Ltd.

202, A-Wing, Galaxy Towers, Plot No-1, Hyderabad Knowledge City, TSIIC, Raidurg, Serilingampally, Rangareddy District, Hyderabad-500081 Telangana, INDIA.

+91-40-2354-9414 /1142 /3311

info@suvenpharm.com

CIN : L24299MH2018PLC422236

Registered Office:

Suven Pharmaceuticals Ltd.

215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India

Reach Us | Terms Of Use | Privacy Policy